Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

News Releases

Date Title and Summary
Toggle Summary electroCore CEO to Join Company’s Board of Directors
Francis R. Amato to Take on Additional Role to Help Further Position the Company for Growth       Basking Ridge, NJ, June 21, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that Chief Executive
Toggle Summary electroCore Announces Appointment of New Chief Medical Officer
Peter Staats MD, MBA, ABIPP, FIPP Joins electroCore to Lead Global Development of Company’s Non-invasive Vagus Nerve Stimulation (nVNS) Therapy   Basking Ridge, NJ, June 21, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological
Toggle Summary electroCore Receives 510(k) Clearance for gammaCore-S® (non-invasive vagus nerve stimulator) for the Acute Treatment of Pain Associated with Episodic Cluster Headache in Adult Patients
Regulatory clearance marks most recent achievement in new device being available to the approximately 400,000 Americans living with episodic cluster headaches     Basking Ridge, NJ, June 15, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through
Toggle Summary New Analysis of ACT Clinical Trial Program Highlights Efficacy and Safety of electroCore’s gammaCore® (non-invasive vagus nerve stimulator) in the Acute Treatment of Episodic Cluster Headache
Data from Pooled Analysis of ACT1 and ACT2 To Be Presented in Late-Breaking Oral Session at Annual Scientific Meeting of the American Headache Society    Basking Ridge, NJ, June 8, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through
Toggle Summary electroCore Announces Data Presentation at the 69th American Academy of Neurology Annual Meeting
Data from ACT2 Clinical Trial of gammaCore ®  in Cluster Headache Presented for First Time Yesterday During Emerging Science Session   Basking Ridge, NJ, April 26, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement,
Toggle Summary FDA Releases gammaCore®, the First Non-Invasive Vagus Nerve Stimulation Therapy Applied at the Neck for Acute Treatment of Pain Associated with Episodic Cluster Headache in Adult Patients
First U.S. Food and Drug Administration (FDA) release for electroCore, a neuroscience and technology company  - Hand-held, non-invasive, easy-to-use device provides new option for the approximately 400,000 Americans living with this rare but extremely debilitating headache disorder  Basking Ridge,
Toggle Summary Mount Sinai Beth Israel Receive Award from The United States Department of Defense to Study Gulf War Illness with electroCore’s non-invasive vagus nerve stimulation therapy
The Pain & Fatigue Study Center at Mount Sinai Beth Israel in New York has been awarded a United States Army Medical Research grant to conduct a study into the treatment of veterans of the 1990-1991 Gulf War who have Gulf War Illness using electroCore’s non-invasive vagus nerve stimulation (nVNS)
Toggle Summary Presentation shows that healthcare costs for patients with a primary headache diagnosis cost four times more than a healthy patient due to comorbidities
Research presented at the Academy of Managed Care Pharmacy (AMCP) Nexus in early October in Washington, DC, showed that 60 percent of adult patients who were diagnosed with primary headache had one or more comorbidities which raised the average annual cost of their healthcare to over $20,000.
Toggle Summary Reorganization of electroCore management team as Frank Amato becomes CEO and founder JP Errico becomes Chief Science and Strategy Officer.
Basking Ridge, New Jersey: Frank Amato, previously Chief Operating Officer, has been appointed Chief Executive Officer of electroCore, the Merck-backed world leader in non-invasive vagus nerve stimulation (nVNS) therapy. This change is part of a management-proposed development plan, unanimously
Toggle Summary ElectroCore’s non-invasive vagus nerve stimulation (nVNS) demonstrates efficacy in preventing cluster headache and menstrual migraine
The results of two studies, presented at the American Headache Society (AHS) Science Meeting last weekend in San Diego, show that using electroCore’s non-invasive vagus nerve stimulation (nVNS) therapy, gammaCore®, is effective at preventing both cluster headache and menstrual migraine.